国产鸽新城疫灭活疫苗获批二类新兽药

Core Viewpoint - The research team led by Professor Wang Chengbao from Northwest A&F University has developed an inactivated vaccine for pigeon Newcastle disease (PN06 strain), which has officially received the national Class II new veterinary drug certificate, marking a significant breakthrough in the independent research and development of biological products for pigeons in China [1]. Group 1: Vaccine Development - The PN06 strain vaccine is the first domestically approved veterinary drug product that has not been formally marketed in China, representing a high innovation benchmark in the veterinary field due to the high development barriers and long cycles associated with vaccine biological products [1]. - The vaccine is designed to address the high morbidity and mortality rates associated with pigeon Newcastle disease, which has historically relied on chicken Newcastle disease vaccines with limited efficacy and frequent immunization failures [1]. Group 2: Research and Testing - Since 2016, the research team has screened advantageous strains from hundreds of disease samples across the country, successfully cultivating the PN06 strain with good immunogenicity after overcoming key technical challenges in virus culture purification and inactivation process optimization [1]. - The vaccine completed laboratory research in 2019 and underwent two years of clinical trials to verify its safety and effectiveness [1]. Group 3: Market Impact - The vaccine is suitable for all breeds and ages of pigeons, with minimal stress response post-vaccination and a protection rate exceeding 90%, along with a long-lasting immune duration [1]. - This development addresses the issues of high prices and mismatched strains associated with imported vaccines, filling a gap in the supply of high-quality domestic vaccines for pigeons [1]. Group 4: Industry Context - China has the largest scale of pigeon farming globally, but the disease prevention and control system remains weak [1]. - The research team has established the most comprehensive resource bank of pigeon source strains and bacterial strains in the country and plans to continue advancing the development of a series of pigeon vaccines and drugs [1].